The Impact of Lipoprotein-Associated Oxidative Stress on Cell-Specific Microvesicle Release in Patients with Familial Hypercholesterolemia

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Nielsen, M H ^a,b   Irvine, H ^c   Vedel, S ^c   Raungaard, B ^b   Beck Nielsen, H ^a   Handberg, A ^b,d  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; CELLS; CHEMICAL ACTIVATION; DISEASES; ENDOTHELIAL CELLS; TENDONS;

ACHILLES TENDONS; CELL ACTIVATION; FAMILIAL HYPERCHOLESTEROLEMIA; LIPID PROFILE; MICROVESICLES; PLASMA CONCENTRATION; SMALL CELLS; TISSUE FACTORS;

CYTOLOGY;

CD36 ANTIGEN; OXIDIZED LOW DENSITY LIPOPROTEIN; THROMBOPLASTIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CELL ACTIVATION; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ERYTHROCYTE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIPID ANALYSIS; MALE; MEMBRANE MICROPARTICLE; MIDDLE AGED; MONOCYTE; OXIDATIVE STRESS; PROTEIN EXPRESSION; THROMBOCYTE; ACHILLES TENDON; COMPLICATION; METABOLISM; PATHOLOGY; REGRESSION ANALYSIS; XANTHOMATOSIS;

ACHILLES TENDON; ANTIGENS, CD36; CELL-DERIVED MICROPARTICLES; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; REGRESSION ANALYSIS; XANTHOMATOSIS;

EID: 84958212844     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/2492858     Document Type: Article

References (55)

1. D. J. Rader, J. Cohen, and H. H. Hobbs, "Monogenic hypercholesterolemia: New insights in pathogenesis and treatment," The Journal of Clinical Investigation, vol. 111, no. 12, pp. 1795-1803, 2003.
2. S. G. Tsouli, D. N. Kiortsis, M. I. Argyropoulou, D. P. Mikhailidis, and M. S. Elisaf, "Pathogenesis, detection and treatment of Achilles tendon xanthomas," European Journal of Clinical Investigation, vol. 35, no. 4, pp. 236-244, 2005.
3. F. Civeira, S. Castillo, R. Alonso et al., "Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1960-1965, 2005.
4. D. N. Kiortsis, M. I. Argyropoulou, V. Xydis, S. G. Tsouli, and M. S. Elisaf, "Correlation of achilles tendon thickness evaluated by ultrasonography with carotid intima-media thickness in patients with familial hypercholesterolemia," Atherosclerosis, vol. 186, no. 1, pp. 228-229, 2006.
5. S. G. Tsouli, D. N. Kiortsis, E. S. Lourida et al., "Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia," Journal of Lipid Research, vol. 47, no. 10, pp. 2208-2214, 2006.
6. M. Hjuler Nielsen, H. Irvine, S. Vedel et al., "Elevated atherosclerosis-related gene expression, monocyte activation and microparticle-release are related to increased lipoprotein-associated oxidative stress in familial hypercholesterolemia," PLoS ONE, vol. 10, no. 4, Article ID e0121516, 2015.
7. E. Verhoye and M. R. Langlois, "Circulating oxidized lowdensity lipoprotein: A biomarker of atherosclerosis and cardiovascular risk?" Clinical Chemistry and Laboratory Medicine, vol. 47, no. 2, pp.128-137, 2009.
8. D. Steinberg and J. L. Witztum, "Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?" Circulation, vol. 105, no. 17, pp. 2107-2111, 2002.
9. Y. M. Park, "CD36, a scavenger receptor implicated in atherosclerosis," Experimental and Molecular Medicine, vol. 46, no. 6, article e99, 2014.
10. R. L. Silverstein, "Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36," Cleveland Clinic Journal of Medicine, vol. 76, no. 2, pp. S27-S30, 2009.
11. D. Steinberg, "Low density lipoprotein oxidation and its pathobiological significance," Journal of Biological Chemistry, vol. 272, no. 34, pp.20963-20966,1997.
12. K. Chen, M. Febbraio, W. Li, and R. L. Silverstein, "A specific cd36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein," Circulation Research, vol. 102, no.12, pp. 1512-1519, 2008.
13. N. Matsumoto, S. Nomura, H. Kamihata, Y. Kimura, and T. Iwasaka, "Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome," Thrombosis and Haemostasis,vol.91,no.1,pp.146-154,2004.
14. H. Wang, Z.-H. Wang, J. Kong et al., "Oxidized low-density lipoprotein-dependent platelet- derived microvesicles trigger procoagulant effects and amplify oxidative stress," Molecular Medicine, vol. 18, no. 2, pp. 159-166, 2012.
15. V.Combes,A.-C.Simon,G.-E.Grauetal.,"Invitrogeneration of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant," The Journal of Clinical Investigation, vol. 104, no. 1, pp. 93-102, 1999.
16. M.-L. Liu, M. P. Reilly, P. Casasanto, S. E. McKenzie, and K. J. Williams, "Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 430-435, 2007.
17. C. Théry, M. Ostrowski, and E. Segura, "Membrane vesicles as conveyors of immune responses," Nature Reviews Immunology, vol. 9, no. 8, pp. 581-593, 2009.
18. P.-E. Rautou, A.-C. Vion, N. Amabile et al., "Microparticles, vascular function, and atherothrombosis," Circulation Research, vol. 109, no. 5, pp. 593-606, 2011.
19. A. S. Leroyer, A. Tedgui, and C. M. Boulanger, "Microparticles and type 2 diabetes," Diabetes and Metabolism, vol. 34, supplement 1, pp. S27-S32, 2008.
20. A. S. Leroyer, A. Tedgui, and C. M. Boulanger, "Role of microparticles in atherothrombosis," Journal of Internal Medicine,vol. 263, no. 5, pp. 528-537, 2008.
21. C. M. Boulanger, N. Amabile, and A. Tedgui, "Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease," Hypertension, vol. 48, no. 2, pp. 180-186, 2006.
22. M. J. VanWijk, E. VanBavel, A. Sturk, and R. Nieuwland, "Microparticles in cardiovascular diseases," Cardiovascular Research, vol. 59, no. 2, pp. 277-287, 2003.
23. A. Angelillo-Scherrer, "Leukocyte-derived microparticles in vascular homeostasis," Circulation Research, vol. 110, no. 2, pp. 356-369, 2012.
24. C. M. Boulanger, A. Scoazec, T. Ebrahimian et al., "Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction," Circulation, vol. 104, no. 22, pp. 2649-2652, 2001.
25. G. N. Chironi, A. Simon, C. M. Boulanger et al., "Circulating microparticles may influence early carotid artery remodeling," Journal of Hypertension, vol. 28, no. 4, pp. 789-796, 2010.
26. S. Nomura, M. Suzuki, K. Katsura et al., "Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus," Atherosclerosis, vol. 116, no. 2, pp. 235-240, 1995.
27. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge," Clinical Chemistry, vol. 18, no. 6, pp. 499-502,1972.
28. M. H. Nielsen, H. Beck-Nielsen, and M. N. Andersen, "A flow cytometric method for characterization of circulating cellderived microparticles in plasma," Journal of Extracellular Vesicles, vol. 3, Article ID 20795, 2014.
29. J. Shi, C. W. Heegaard, J. T. Rasmussen, and G. E. Gilbert, "Lactadherin binds selectively to membranes containing phosphatidyl-L-serine and increased curvature," Biochimica et Biophysica Acta-Biomembranes, vol. 1667, no. 1, pp. 82-90, 2004.
30. J.Shi, Y. Shi, L.N. Waehrens, J.T. Rasmussen, C.W. Heegaard, and G.E.Gilbert,"Lactadherin detects early phosphatidylserine exposure on immortalized leukemia cells undergoing programmed cell death," Cytometry A, vol. 69, no.12, pp. 1193-1201, 2006.
31. R. A. Preston, W. Jy, J. J. Jimenez et al., "Effects of severe hypertension on endothelial and platelet microparticles," Hypertension, vol. 41, no. 2, pp. 211-217, 2003.
32. M. E. Tushuizen, M. Diamant, A. Sturk, and R. Nieuwland, "Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe?" Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 1, pp. 4-9, 2011.
33. C. N. França, M. C. Izar, J. B. Amaral, D. M. Tegani, and F. A. Fonseca, "Microparticles as potential biomarkers of cardiovascular disease," Arquivos Brasileiros de Cardiologia, vol. 104, no. 2, pp. 169-174, 2015.
34. A.C.Goldberg,P.N.Hopkins,P.P.Tothetal.,"Familialhypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia," Journal of Clinical Lipidology, vol. 5, no. 3, pp. 133-140, 2011.
35. R. Suades, T. Padró, R. Alonso, P. Mata, and L. Badimon, "Lipidlowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells," Thrombosis and Haemostasis, vol. 110, no. 2, pp. 366-377, 2013.
36. R. Suades, T. Padró, R. Alonso, J. López-Miranda, P. Mata, and L. Badimon, "Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients," Thrombosis and Haemostasis, vol. 111, no. 1, pp. 111-121, 2014.
37. F. Dignat-George and C. M. Boulanger, "The many faces of endothelial microparticles," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 1, pp. 27-33, 2011.
38. E. J. van Beers, M. C. L. Schaap, R. J. Berckmans et al., "Circulating erythrocyte-derived microparticles are associated with coagulationactivationinsicklecelldisease,"Haematologica, vol. 94, no. 11, pp. 1513-1519, 2009.
39. R. L. Koshiar, S. Somajo, E. Norström, B. Dahlbäck, and T. Miyata, "Erythrocyte-derived microparticles supporting activated protein c-mediated regulation of blood coagulation," PLoS ONE, vol. 9, no. 8, Article ID e104200, 2014.
40. A. S. Shet, O. Aras, K. Gupta et al., "Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes," Blood, vol.102, no. 7, pp. 2678-2683, 2003.
41. É. Biró, K. N. Sturk-Maquelin, G. M. T. Vogel et al., "Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner," Journal of Thrombosis and Haemostasis, vol. 1, no. 12, pp. 2561-2568, 2003.
42. A. P. Owens III and N. MacKman, "Microparticles in hemostasis and thrombosis," Circulation Research, vol. 108, no. 10, pp. 1284-1297, 2011.
43. J.-G.Wang,J.C.Williams,B.K.Davisetal.,"Monocyticmicroparticles activate endothelial cells in an IL-1β-dependent manner," Blood, vol. 118, no. 8, pp. 2366-2374, 2011.
44. A. P. Owens III and N. MacKman, "Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque," Thrombosis Research, vol. 129, supplement 2, pp. S30-S33, 2012.
45. A. P. Owens III, F. H. Passam, S. Antoniak et al., "Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin," The Journal of Clinical Investigation, vol. 122, no. 2, pp. 558-568, 2012.
46. M. B. Fessler, K. Rose, Y. Zhang, R. Jaramillo, and D. C. Zeldin, "Relationship between serum cholesterol and indices of erythrocytes and platelets in the US population," Journal of Lipid Research, vol. 54, no. 11, pp. 3177-3188, 2013.
47. P. M. Moriarty and C. A. Gibson, "Association between hematological parameters and high-density lipoprotein cholesterol," Current Opinion in Cardiology, vol. 20, no. 4, pp. 318-323, 2005.
48. A. Blum, "The possible role of red blood cell microvesicles in atherosclerosis," European Journal of Internal Medicine, vol. 20, no. 2, pp. 101-105, 2009.
49. S. Nomura, A. Shouzu, S. Omoto, M. Nishikawa, T. Iwasaka, and S. Fukuhara, "Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes," Clinical and Applied Thrombosis/Hemostasis, vol. 10, no. 3, pp. 205-215, 2004.
50. M. Nagahama, S. Nomura, S. Kanazawa, Y. Ozaki, H. Kagawa, and S. Fukuhara, "Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in anti-phospholipid antibody syndrome," Autoimmunity, vol. 36, no. 3, pp. 125-131, 2003.
51. R. Nergiz-Unal, T. Rademakers, J. M. M. Cosemans, and J. W. M. Heemskerk, "Cd36 as a multiple-ligand signaling receptor in atherothrombosis," Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 9, no. 1, pp. 42-55, 2011.
52. R. Nergiz-Unal, M. M. E. Lamers, R. Van Kruchten et al., "Signaling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low density lipoprotein," Journal of Thrombosis and Haemostasis, vol. 9, no. 9, pp. 1835-1846, 2011.
53. R.Lacroix, S.Robert, P.Poncelet, R.S.Kasthuri, N.S.Key, and F. Dignat-George, "Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: Results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop," Journal of Thrombosis and Haemostasis, vol. 8, no. 11, pp. 2571-2574, 2010.
54. R. Lacroix, S. Robert, P. Poncelet, and F. Dignat-George, "Overcoming limitations of microparticle measurement by flow cytometry," Seminars in Thrombosis and Hemostasis, vol. 36, no. 8, pp. 807-818, 2010.
55. E. van der Pol, M. J. C. van Gemert, A. Sturk, R. Nieuwland, and T. G. van Leeuwen, "Single vs. swarm detection of microparticles and exosomes by flow cytometry," Journal of Thrombosis and Haemostasis, vol. 10, no. 5, pp. 919-930, 2012.